|
Volumn 366, Issue 9480, 2005, Pages 118-120
|
Deep vein thrombosis [2] (multiple letters)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTICOAGULANT AGENT;
ANTIVITAMIN K;
BLOOD CLOTTING FACTOR 10;
BLOOD CLOTTING FACTOR 8;
VON WILLEBRAND FACTOR;
WARFARIN;
ANTICOAGULANT THERAPY;
BLEEDING;
BLOOD GROUP ABO SYSTEM;
BLOOD LEVEL;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DEEP VEIN THROMBOSIS;
DRUG EFFICACY;
DRUG WITHDRAWAL;
GENE LINKAGE DISEQUILIBRIUM;
GENE LOCUS;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
LETTER;
LONG TERM CARE;
PHENOTYPE;
PRIORITY JOURNAL;
RECURRENCE RISK;
RISK FACTOR;
THROMBOSIS PREVENTION;
TREATMENT OUTCOME;
VENOUS THROMBOEMBOLISM;
NOTE;
RECURRENT DISEASE;
VEIN THROMBOSIS;
BLOOD;
GENETICS;
GENOTYPE;
ANTICOAGULANTS;
HUMANS;
RECURRENCE;
VENOUS THROMBOSIS;
WARFARIN;
ABO BLOOD-GROUP SYSTEM;
FACTOR VIII;
GENOTYPE;
PHENOTYPE;
RISK FACTORS;
VON WILLEBRAND FACTOR;
|
EID: 22244479992
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(05)66858-4 Document Type: Letter |
Times cited : (7)
|
References (5)
|